ZVRA logo

ZVRA
Zevra Therapeutics Inc

23,988
Mkt Cap
$494.86M
Volume
819,522.00
52W High
$13.16
52W Low
$6.19
PE Ratio
13.93
ZVRA Fundamentals
Price
$8.98
Prev Close
$8.79
Open
$8.71
50D MA
$8.78
Beta
0.89
Avg. Volume
717,753.32
EPS (Annual)
-$2.28
P/B
3.71
Rev/Employee
$400,203.39
$376.54
Loading...
Loading...
News
all
press releases
Royce & Associates LP Takes Position in Zevra Therapeutics, Inc. $ZVRA
Royce & Associates LP acquired a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +6.06% and +4.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Tuesday
Zevra Therapeutics (NASDAQ:ZVRA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·4d ago
News Placeholder
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -9.59% and -33.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -150.00% and -9.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat...
MarketBeat·10d ago
News Placeholder
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevras executive officers and whether investor...
Business Wire·17d ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling...
MarketBeat·18d ago
News Placeholder
Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy Sangiovanni sold 3,000 shares of the company's stock in a transaction dated Tuesday, February 3rd. The shares were sold at an...
MarketBeat·30d ago
News Placeholder
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CEO Neil Mcfarlane sold 91,000 shares of the firm's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price...
MarketBeat·1mo ago
<
1
2
...
>

Latest ZVRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.